drugset / Trial / NCT00620230

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

NCT00620230 ↗

Phase 1 Completed 46 enrolled Novartis
RandomizedParallel-groupDouble-blind

Summary

This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.

Timeline

Start
2007-10
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator NVP-VAK694 Unknown — —

Indications